Results 221 to 230 of about 177,383 (332)

TGFβ1 attenuates microglial IL1β release through inhibition of NLRP3 inflammasome priming. [PDF]

Front Immunol
Kalischer C, Potru PS, Lehmann N, Jahn J, Rupp NL, Vidovic N, Russ T, Wiemann S, Spittau B.   +8 more
europepmc   +1 more source

["The inflammasomes"].

Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2012
Inflammation is a host adaptational response to cell injury caused by various exogenous and endogenous stimuli. IL-1β, which is an important proinflammatory cytokine secreted at the site of cellular injury, plays an important role in inflammation. Inflammasome is an intracellular multi-protein complex that mediates caspase-1-dependent processing of IL ...
openaire   +1 more source

Decision tree analysis as a preliminary evidence‐based tool for identifying the syndrome of undifferentiated recurrent fever in children compared with hereditary recurrent fevers and periodic fever, aphthosis, pharyngitis and adenitis syndrome

Arthritis &Rheumatology, Accepted Article.
Objective To develop evidence‐based criteria to classify SURF patients. Methods 112 SURF patients followed in a single tertiary referral center were analyzed. Patients with genetically confirmed hereditary recurrent fever (HRF) or with periodic fever, aphthosis, pharyngitis and adenitis (PFAPA) syndrome already analyzed for the Eurofever classification
Riccardo Papa, Francesca Bovis, Silvia Federici, Serena Palmeri, Marta Bustaffa, Giada Recchi, Roberta Bertelli, Roberta Caorsi, Stefano Volpi, Sabrina Fuehner, Veysel Cam, Anna Kozáková, Šárka Horáčková Fingerhutová, Antonella Insalaco, Dirk Foell, Seza Ozen, Isabella Ceccherini, Marco Gattorno, on behalf of the Eurofever study group for the Classification criteria of recurrent fevers and PerSAID project, Michael Hofer, Federica Vanoni, Jordi Anton, Juan Ignacio Arostegui, Karyl S. Barron, Eldad Ben‐Chetrit, Paul Brogan, Luca Cantarini, Isabella Ceccherini, Fabrizio De Benedetti, Fatma Dedeoglu, Erkan Demirkaya, Joost Frenke, Raphaela Goldbach‐Mansky, Ahmet Gul, Veronique Hentgen, Hal M. Hoffman, Tilmann Kallinich, Isabelle Koné‐Paut, Jasmin Kuemmerle‐Deschner, Helen J. Lachmann, Ronald M. Laxer, Avi Livneh, Laura Obici, Dorota Rowczenio, Ricardo Russo, Yael Shinar, Anna Simon, Natasa Toplak, Isabelle Touitou, Yosef Uziel, Marielle van Gijn, Daniel L. Kastner, Alberto Martini, Maria Pia Sormani, Nicolino Ruperto   +54 more
wiley   +1 more source

Dead or alive: how the immune system detects microbial viability

, 2019
Sander, L., Ugolini, M.
core   +1 more source

The inflammasome is activated during late EBV lytic replication.

Qingping Lan (10315435), Xiaolin Zhang (246784), Yifan Sun (734245), Jing Yang (13969), Xiaojuan Li (351842), Ersheng Kuang (129028)   +5 more
openalex   +1 more source

Interleukin‐18 levels are associated with disease course in patients with Still's disease treated with IL‐1 inhibitors

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the prognostic utility of circulating Interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in Still's disease (SD) patients receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna de Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe   +8 more
wiley   +1 more source

Familial Mediterranean Fever: A Comprehensive Review of Pathogenesis, Genetics, and Epigenetic Regulation. [PDF]

Balkan Med J
Ugurlu S, Kilinc OC, Karacan I, Parlar K.   +3 more
europepmc   +1 more source

Figure 6. MAF1Type I inhibits AIM2 inflammasome activation by inhibiting mtDNA release.

Holness, Nadia
openalex   +1 more source

Inflammasomes and Metabolic Disease [PDF]

, 2013
Jorge Henao‐Mejia, Eran Elinav, Christoph A. Thaiss, Richard A. Flavell   +3 more
openalex   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source